ReviewClinical pharmacology : advances and applications2021
Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.
Review in Clinical pharmacology : advances and applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pharmacological Management of Stress Urinary Incontinence with Atypical Leakage Features, Symptom Response to Short-term Solifenacin Trial.International urogynecology journal · 2026Article
- Comment on "Pharmacological Management of Stress Urinary Incontinence with Atypical Leakage Features, Symptom Response to Short-term Solifenacin Trial".International urogynecology journal · 2026Article
- Real-world persistence of vibegron in patients aged ≥ 80 years with overactive bladder: a multicenter cohort study.World journal of urology · 2026Observational
- Internet Health Information-Seeking Trend of Urinary Incontinence in Mainland China: Infodemiology Study.JMIR formative research · 2025Article
- Lower Urinary Tract Disorders as Adverse Drug Reactions-A Literature Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Mixed urinary incontinence: Are there effective treatments?Neurourology and urodynamics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological management of urinary incontinence (UI) is currently based on antimuscarinic and beta-3-agonist drugs. Botulinum toxin A detrusor injections represent an effective but more invasive alternative. This review covers the latest developments of the currently available drugs and the emerging compounds for the treatment of UI. Evidence shows that new antimuscarinics and beta-3-agonists with improved safety profiles may offer unique options to patients intolerant to currently available drugs. Combination therapy proved to be a non-invasive alternative for patients refractory to first-line monotherapy. Exciting advances are ongoing in the research to improve the efficacy/tolerability profile of botulinum toxin, through innovative routes of administration. Several new agents emerged from preclinical studies, some of which have now entered the clinical phase of development and could represent, in the coming years, a new way for the treatment of UI. Recent evidence on the existence of different overactive bladder phenotypes could be the key to tailored treatment. Rather than discovering new molecules, reaching the ability to identify the right drug for the right patient could be the real gamechanger of the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.